|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4300 - 0.4300|
|52 Week Range||0.1100 - 1.9500|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2020 - Jun 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Despite the difficulties presented by the COVID-19 Pandemic, the Company continues to make progress on developing its proprietary Medical Robotic System. As AVRA CEO Barry Cohen explains, “The latest test results of AVRA’s Imaging and Detection System software designed to Detect, Identify, Diagnose, and Deliver an autonomous robotic surgical procedure continue to reinforce our confidence in our ability to develop an autonomous Medical Robotic System which should enable surgeons to sharply increase their productivity while also improving patient outcomes in the operating room of the future.”
AVRA Medical Robotics, Inc. (the “Company”) (AVMR), an artificial intelligence company building a fully autonomous medical robotic system combining artificial intelligence, machine learning and proprietary software, today announces that its Chairman & CEO, Barry Cohen, has increased his stake in the company by approximately 5% by purchasing an additional 1,000,000 common shares of AVRA stock. The shares will be restricted.
ORLANDO, Fla., Feb. 03, 2020 -- AVRA Medical Robotics, Inc. (the “Company”) (OTCQB: AVMR), a medical software and artificial intelligence company building a fully autonomous.